CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma Market Outlook

Thelansis’s “CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma Overview

Mantle cell lymphoma (MCL) is a mature B-cell subtype of Non-Hodgkin lymphoma (NHL), characterized by translocation, primarily caused by an excessive expression of Cyclin D1. Although with the progress in our knowledge of the causes of MCL and available treatments for MCL, this cancer is still incurable. Poor prognostic indicators, such as age, male gender, rapid disease progression, significant nodal involvement, elevated serum lactate dehydrogenase level, increased expression of Ki-67, and TP53 mutation, are associated with an unfavorable outcome. The symptoms of MCL are similar to NHL, including lymphadenopathy, lymphocytosis, splenic enlargement, growth in Waldeyer’s ring and tonsils, lymphomatous polyposis, and bone marrow infiltration. Interestingly, some patients may remain asymptomatic despite lymphocytosis. MCL can affect various extranodal sites, including the kidneys, soft tissues, skin, and the central nervous system (CNS). Non-nodal leukemic MCL often presents as asymptomatic indolent or ‘smouldering’ MCL. Advanced immunotherapy utilizing chimeric antigen receptor (CAR)-T cells shows promise in treating B-cell malignancies and MCL. Targeting B-cell antigens on the cell surface has proven effective in recurrent (R/R) MCL, as observed in other B-cell cancers. The USFDA has approved brexucabtagene autoleucel (Tecartus, KTE-X19), a novel CAR T-cell therapy, for use in MCL patients who have not responded to previous treatments or have experienced a relapse.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: CAR T-Cell Therapy Opportunity within Mantle Cell Lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034